Group 1 - The core point of the announcement is that the controlling shareholder, Mr. Ke Jinlong, has released a portion of his pledged shares, specifically 31,680,000 shares, which represents 15.31% of his total holdings and 2.78% of the company's total share capital [1][1][1] Group 2 - The specific details of the share release include the number of shares released and the percentage of total holdings affected [1][1] - The announcement confirms that the release of the pledge has been completed and the registration procedures have been finalized [1]

Group 1 - The core announcement is about the release of part of the pledged shares by the controlling shareholder, Mr. Ke Jinlong, who has released 31,680,000 shares [1][3] - The released shares represent 15.31% of Mr. Ke Jinlong's total holdings and 2.78% of the company's total share capital [3] - The announcement confirms that the company’s board of directors guarantees the truthfulness, accuracy, and completeness of the content [1] Group 2 - The announcement was made on October 28, 2025, following the completion of the pledge release registration procedures [3] - The document includes a reminder that all data in the tables may have rounding differences [1]

Core Points - Dacilin announced on October 27 that it received a notification from its controlling shareholder, Mr. Ke Jinlong, regarding the release of a portion of his pledged shares, totaling 31,680,000 shares [1] Summary by Category Company Actions - Dacilin has completed the registration procedures for the release of the pledged shares [1] Shareholder Information - Mr. Ke Jinlong, a controlling shareholder, is the individual who notified the company about the release of the pledged shares [1]

证券代码：603233 证券简称：大参林 公告编号：2025-063 大参林医药集团股份有限公司 关于控股股东部分股份解除质押的公告 一、本次股份解除质押的具体情况 | | | | | | | | | 已质押股份情况 | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其所 | 占公 | | | 况 | 未质 | | | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 持股份 | 司总 | 已质押 | 已质押 | 未质押 | 押股 | | 股东名称 | （股） | 比例 | 累计质押数 | 累计质押数 | 比例 | 股本 | 股份中 | 股份中 | 股份中 | 份中 | | | | (%) | 量（股） | 量（股） | | 比例 | 限售股 | | 限售股 | | | | | | | | （%） | （%） | 份数量 | 冻结股 | 份数量 | 冻结 | | | | | | | | | | 份数量 | | 股份 | | | | | | | | | （股） | | ...

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

| 证券代码：603233 | 证券简称：大参林 | 公告编号：2025-062 | | --- | --- | --- | | 债券代码：113605 | 债券简称：大参转债 | | 因公司实施 2025 年半年度权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113605 | 大参转债 | 可转债转股停牌 | 2025/10/29 | | | | 一、权益分派的基本情况 2025 年 9 月 15 日，公司召开了 2025 年第二次临时股东大会，审议通过了《关 于公司 2025 年半年度利润分配方案的议案》，拟以实施权益分派股权登记日的总 股本扣减回购部分的股份为基数分配利润，向全体股东每股派发现金股利人民币 0.34 元(含税),不送红股，不进行资本公积转增股本。在实施权益分派的股权登记 日前公司总股本发生变动的，拟维持分配比例不变，相应调整分配总额。 本次权益分派实施后，公司将依据《大参林公开发行可转换公司债券 ...

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Core Points - Dazhonglin's stock price increased by 2.07% on October 21, reaching 18.77 CNY per share, with a total market capitalization of 21.376 billion CNY [1] - The company has seen a year-to-date stock price increase of 27.25%, with a 5-day increase of 11.66% and a 20-day increase of 8.56% [1] - Dazhonglin's main business includes retail of traditional Chinese and Western medicine, health products, and medical devices, with 76.88% of revenue coming from Western and Chinese medicine [1] Financial Performance - For the first half of 2025, Dazhonglin reported revenue of 13.523 billion CNY, a year-on-year increase of 1.33%, and a net profit of 798 million CNY, up 21.38% [2] - The company has distributed a total of 3.355 billion CNY in dividends since its A-share listing, with 1.624 billion CNY distributed in the last three years [3] Shareholder Information - As of June 30, 2025, Dazhonglin had 31,500 shareholders, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per shareholder, an increase of 11.20% [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 90.448 million shares, an increase of 12.4318 million shares from the previous period [3]

Market Overview - The pharmaceutical commercial sector increased by 1.19% on October 20, with Dazhenlin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Dazhenlin (603233) closed at 18.39, up 5.09%, with a trading volume of 138,100 shares and a turnover of 251 million yuan [1] - Jianfa Zhixin (301584) closed at 29.30, up 4.46%, with a trading volume of 186,400 shares and a turnover of 534 million yuan [1] - Yao Yigou (300937) closed at 27.19, up 3.74%, with a trading volume of 18,200 shares and a turnover of 4.88 million yuan [1] - Guofang Co. (600538) closed at 5.81, up 3.20%, with a trading volume of 92,900 shares and a turnover of 5.35 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 11.55 million yuan from institutional funds, while retail investors saw a net inflow of 21.80 million yuan [2] - The main stocks with significant capital flow include Shanghai Pharmaceuticals (601607) with a net inflow of 16.68 million yuan from institutional funds [3] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 16.68 million yuan from institutional funds, but a net outflow of 22.35 million yuan from retail investors [3] - Dazhenlin (603233) saw a net inflow of 11.68 million yuan from institutional funds, with a net outflow of 15.05 million yuan from retail investors [3] - Laobaixing (603883) had a net inflow of 6.98 million yuan from institutional funds, but also faced a net outflow of 1.86 million yuan from retail investors [3]